Advanced search
Publication Cover
Expert Opinion on Medical Diagnostics Volume 1, 2007 - Issue 4
Journal homepage
29
Views
0
CrossRef citations to date
0
Altmetric
Review

Prognostic markers of astrocytoma: how to predict the unpredictable?

Fatima W Khwaja Shaukat Khanum Memorial Cancer Hospital and Research Center, Basic Science Lab, Abdul Hafeez Research Wing, 77A, Block R/8, Lahore, 54000, Pakistan +92 042 5180727 ext. 2523; +92 042 5945207; [email protected]
, PhD (Junior Research Scientist)
Pages 463-479 | Published online: 29 Nov 2007

Bibliography

  • BELDA-INIESTA C, DE CASTRO CARPENO J, CASADO SAENZ E et al.: Molecular biology of malignant gliomas. Clin. Transl. Oncol. (2006) 8(9):635-641.
  • LOUIS DN OH, WIESTLER OD, CAVENEE WK et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. (Berl.) (2007) 114(2):97-109.
  • PIETSCH T, WIESTLER OD: Molecular neuropathology of astrocytic brain tumors. J. Neurooncol. (1997) 35(3):211-222.
  • PRADOS MD, LEVIN V: Biology and treatment of malignant glioma. Semin. Oncol. (2000) 27(3 Suppl. 6):1-10.
  • SCHWARTZ SA, WEIL RJ, THOMPSON RC et al.: Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res. (2005) 65(17):7674-7681.
  • SHIH HA, BETENSKY RA, DORFMAN MV et al.: Genetic analyses for predictors of radiation response in glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. (2005) 63(3):704-710.
  • HOUILLIER C, LEJEUNE J, BENOUAICH-AMIEL A et al.: Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer (2006) 106(10):2218-2223.
  • STUPP R, RENI M, GATTA G, MAZZA E, VECHT C: Anaplastic astrocytoma in adults. Crit. Rev. Oncol. Hematol. (2007) 63(1):72-80.
  • ULUTIN C, FAYDA M, AKSU G et al.: Primary glioblastoma multiforme in younger patients: a single-institution experience. Tumori (2006) 92(5):407-411.
  • GROVES MD, PUDUVALLI VK, CHANG SM et al.: A North American brain tumor consortium (NABTC 99-04) Phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J. Neurooncol. (2007) 81(3):271-277.
  • PICCIRILLI M, BISTAZZONI S, GAGLIARDI FM et al.: Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori (2006) 92(2):98-103.
  • STARK AM, NABAVI A, MEHDORN HM, BLOMER U: Glioblastoma multiforme – report of 267 cases treated at a single institution. Surg. Neurol. (2005) 63(2):162-169; discussion 169.
  • BUCKNER JC, O'FALLON JR, DINAPOLI RP et al.: Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. J. Neurooncol. (2007) 84(3):279-286.
  • JEREMIC B, MILICIC B, GRUJICIC D et al.: Clinical prognostic factors in patients with malignant glioma treated with combined modality approach. Am. J. Clin. Oncol. (2004) 27(2):195-204.
  • HOBBS SK, SHI G, HOMER R et al.: Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J. Magn. Reson. Imaging (2003) 18(5):530-536.
  • HANEY SM, THOMPSON PM, CLOUGHESY TF et al.: Mapping therapeutic response in a patient with malignant glioma. J. Comput. Assist. Tomogr. (2001) 25(4):529-536.
  • AGHI M, GAVIANI P, HENSON JW et al.: Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin. Cancer Res. (2005) 11(24 Part 1):8600-8605.
  • DI COSTANZO A, TROJSI F, GIANNATEMPO GM et al.: Spectroscopic, diffusion and perfusion magnetic resonance imaging at 3.0 Tesla in the delineation of glioblastomas: preliminary results. J. Exp. Clin. Cancer Res. (2006) 25(3):383-390.
  • HIGANO S, YUN X, KUMABE T et al.: Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology (2006) 241(3):839-846.
  • TALOS IF, ZOU KH, KIKINIS R, JOLESZ FA: Volumetric assessment of tumor infiltration of adjacent white matter based on anatomic MRI and diffusion tensor tractography. Acad. Radiol. (2007) 14(4):431-436.
  • ULMER S, BRAGA TA, BARKER FG II et al.: Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology (2006) 67(9):1668-1670.
  • WEI CW, GUO G, MIKULIS DJ: Tumor effects on cerebral white matter as characterized by diffusion tensor tractography. Can. J. Neurol. Sci. (2007) 34(1):62-68.
  • BOLDORINI R, PAGANI E, CAR PG et al.: Molecular characterisation of JC virus strains detected in human brain tumours. Pathology (2003) 35(3):248-253.
  • FARIA MH, GONCALVES BP, DO PATROCINIO RM, DE MORAES-FILHO MO, RABENHORST SH: Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology (2006) 26(6):519-527.
  • SHAFFREY ME, FARACE E, SCHIFF D et al.: The Ki-67 labeling index as a prognostic factor in grade II oligoastrocytomas. J. Neurosurg. (2005) 102(6):1033-1039.
  • MACHEN SK, PRAYSON RA: Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases. Hum. Pathol. (1998) 29(12):1511-1516.
  • PRAYSON RA, KHAJAVI K, COMAIR YG: Cortical architectural abnormalities and MIB1 immunoreactivity in gangliogliomas: a study of 60 patients with intracranial tumors. J. Neuropathol. Exp. Neurol. (1995) 54(4):513-520.
  • JAROS E, PERRY RH, ADAM L et al.: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br. J. Cancer (1992) 66(2):373-385.
  • UEMATSU M, OHSAWA I, AOKAGE T et al.: Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J. Neurooncol. (2005) 72(3):231-238.
  • BOWERS DC, GARGAN L, KAPUR P et al.: Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J. Clin. Oncol. (2003) 21(15):2968-2973.
  • ENESTROM S, VAVRUCH L, FRANLUND B, NORDENSKJOLD B: Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas. Neurochirurgie (1998) 44(1):25-30.
  • SHINODA J, SAKAI N, NAKATANI K, FUNAKOSHI T: Prognostic factors in supratentorial WHO grade II astrocytoma in adults. Br. J. Neurosurg. (1998) 12(4):318-324.
  • HAAPASALO JMA, HELEN P, HAAPASALO H, ISOLA J: Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas. J. Clin. Pathol. (2005) 58(3):263-268.
  • GUDINAVICIENE I, PRANYS D, JUOZAITYTE E: Impact of morphology and biology on the prognosis of patients with gliomas. Medicina (Kaunas) (2004) 40(2):112-120.
  • GIANNINI C, SCHEITHAUER BW, BURGER PC et al.: Cellular proliferation in pilocytic and diffuse astrocytomas. J. Neuropathol. Exp. Neurol. (1999) 58(1):46-53.
  • TORP SH, GRANLI US: Proliferative activity in human glioblastomas assessed by various techniques. Apmis (2001) 109(12):865-869.
  • KANG X, XIAO X, HARATA M et al.: Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas. Cancer Gene Ther. (2006) 13(4):385-392.
  • GUHA A, MUKHERJEE J: Advances in the biology of astrocytomas. Curr. Opin. Neurol. (2004) 17(6):655-662.
  • GODARD S, GETZ G, DELORENZI M et al.: Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. (2003) 63(20):6613-6625.
  • POPKO B, PEARL DK, WALKER DM et al.: Molecular markers that identify human astrocytomas and oligodendrogliomas. J. Neuropathol. Exp. Neurol. (2002) 61(4):329-338.
  • BURGER PC: Revising the World Health Organization (WHO) Blue Book – ‘Histological typing of tumours of the central nervous system’. J. Neurooncol. (1995) 24(1):3-7.
  • STOCKHAMMER G, OBWEGESER A, KOSTRON H et al.: Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol. (Berl.) (2000) 100(1):101-105.
  • SHIM JW, KOH YC, AHN HK et al.: Expression of bFGF and VEGF in brain astrocytoma. J. Korean Med. Sci. (1996) 11(2):149-157.
  • KAUR B, BRAT DJ, CALKINS CC, VAN MEIR EG: Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am. J. Pathol. (2003) 162(1):19-27.
  • ZIEMER LS, KOCH CJ, MAITY A et al.: Hypoxia and VEGF mRNA expression in human tumors. Neoplasia (2001) 3(6):500-508.
  • GIANNOPOULOU E, RAVAZOULA P, KALOFONOS H, MAKATSORIS T, KARDAMAKIS D: Expression of HIF-1alpha and iNOS in astrocytic gliomas: a clinicopathological study. In Vivo (2006) 20(3):421-425.
  • COMPOSTELLA A, TOSONI A, BLATT V, FRANCESCHI E, BRANDES AA: Prognostic factors for anaplastic astrocytomas. J. Neurooncol. (2007) 81(3):295-303.
  • RONG Y DD, VAN MEIR EG, BRAT DJ: “Pseudopalisading” necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J. Neuropathol. Exp. Neurol. (2006) 65(6):529-539.
  • LIU X, CHEN N, WANG X et al.: Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules. J. Neuropathol. Exp. Neurol. (2006) 65(9):905-913.
  • BODEY B, BODEY V, SIEGEL SE et al.: Immunocytochemical detection of members of the caspase cascade of apoptosis in high-grade astrocytomas. In Vivo (2004) 18(5):593-602.
  • KHWAJA FW, REED MS, OLSON JJ et al.: Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J. Proteome Res. (2007) 6(2):559-570.
  • GLASKER S, LONSER RR, OKAMOTO H et al.: Proteomic profiling: a novel method for differential diagnosis? Cancer Biol. Ther. (2007) 6(3):343-345.
  • ROVERSI G, PFUNDT R, MORONI RF et al.: Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene (2006) 25(10):1571-1583.
  • YOON KS LM, KANG SS, KIM JH et al.: p53 mutation and epidermal growth factor receptor overexpression in glioblastoma. J. Korean Med. Sci. (2001) 16(4):481-488.
  • NEWCOMB EW, COHEN H, LEE SR et al.: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. (1998) 8(4):655-667.
  • FULTS D, BROCKMEYER D, TULLOUS MW, PEDONE CA, CAWTHON RM: p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res. (1992) 52(3):674-679.
  • GHIMENTI C, FIANO V, CHIADO-PIAT L et al.: Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets. J. Neurooncol. (2003) 61(2):95-102.
  • BATCHELOR TT, BETENSKY RA, ESPOSITO JM et al.: Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin. Cancer Res. (2004) 10(1 Part 1):228-233.
  • BEGNAMI MD, RUSHING EJ, EVANGELISTA R, SANTI M, QUEZADO M: Evaluation of RB gene and cyclin-dependent kinase inhibitors P21 and P27 in pleomorphic xantoastrocytoma. Int. J. Surg. Pathol. (2006) 14(2):113-118.
  • HENSON JW, SCHNITKER BL, CORREA KM et al.: The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann. Neurol. (1994) 36(5):714-721.
  • HULLEMAN E, HELIN K: Molecular mechanisms in gliomagenesis. Adv. Cancer Res. (2005) 94:1-27.
  • PARSA AT, WALDRON JS, PANNER A et al.: Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. (2007) 13(1):84-88.
  • WEBER R, HOISCHEN A, EHRLER M et al.: Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytoma. Oncogene (2007) 26(7):1088-1097.
  • BACKLUND LM NB, GOIKE HM: Short postoperative survival in patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin. Cancer Res. (2003) 9(4):4151-4158.
  • SMITH JS, TACHIBANA I, PASSE SM et al.: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer. Inst. (2001) 93:1246-1256.
  • KRAUS JA, GLESMANN N, BECK M et al.: Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J. Neurooncol. (2000) 48(2):89-94.
  • KAJIWARA Y, YAMASAKI F, HAMA S et al.: Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer (2003) 97(4):1077-1083.
  • VAN DEN BOOM J, WOLTER M, BLASCHKE B, KNOBBE CB, REIFENBERGER G: Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction. Int. J. Cancer (2006) 119(10):2330-2338.
  • MAHER EA, BRENNAN C, WEN PY et al.: Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. (2006) 66(23):11502-11513.
  • PHILLIPS HS, KHARBANDA S, CHEN R et al.: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 9(3):157-173.
  • KAVSAN V, SHOSTAK K, DMITRENKO V et al.: Characterization of genes with increased expression in human glioblastomas. Tsitol. Genet. (2005) 39(6):37-49.
  • LIANG Y, DIEHN M, WATSON N et al.: Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl. Acad. Sci. USA (2005) 102(16):5814-5819.
  • LIANG Y, BOLLEN AW, ALDAPE KD, GUPTA N: Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer (2006) 6:97.
  • RICH JN, HANS C, JONES B et al.: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. (2005) 65(10):4051-4058.
  • KAVSAN VM, DMITRENKO VV, SHOSTAK KO et al.: Comparison of microarray and sage techniques in gene expression analysis of human glioblastoma. Tsitol. Genet. (2007) 41(1):36-55.
  • LARKIN JE, FRANK BC, GAVRAS H, SULTANA R, QUACKENBUSH J: Independence and reproducibility across microarray platforms. Nat. Methohds (2005) 2(5):337-344.
  • WANG Y, BARBACIORU C, HYLAND F et al.: Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics (2006) 7:59.
  • PUCHADES M, NILSSON CL, EMMETT MR et al.: Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. J. Proteome Res. (2007) 6(2):869-875.
  • SHIM JH, KIM YS, BAHK YY: Proteome profile changes that are differentially regulated by lipid and protein phosphatase activities of tumor suppressor PTEN in PTEN-expressing U-87 MG human glioblastoma cells. Proteomics (2006) 6(1):81-93.
  • KHWAJA FW, DUKE-COHAN JS, BRAT DJ, VAN MEIR EG: Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration. Clin. Cancer Res. (2006) 12(21):6331-6336.
  • PERDIKI M, KORKOLOPOULOU P, THYMARA I et al.: Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Mol. Cell. Biochem. (2007) 295(1-2):75-83.
  • EHRMANN J, KOLAR Z, MOKRY J: Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumours. J. Clin. Pathol. (2005) 58(2):222-223.
  • BALL G, MIAN S, HOLDING F et al.: An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics (2002) 18(3):395-404.
  • KHWAJA FW, NOLEN JD, MENDRINOS SE et al.: Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics (2006) 6(23):6277-6287.
  • LI J, ZHUANG Z, OKAMOTO H et al.: Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers. Neurology (2006) 66(5):733-736.
  • ODREMAN F, VINDIGNI M, GONZALES ML et al.: Proteomic studies on low- and high-grade human brain astrocytomas. J. Proteome Res. (2005) 4(3):698-708.
  • VOGEL TW, ZHUANG Z, LI J et al.: Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin. Cancer Res. (2005) 11(10):3624-3632.
  • FURUTA M, WEIL RJ, VORTMEYER AO et al.: Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene (2004) 23(40):6806-6814.
  • KENNEDY S: Proteomic profiling from human samples: the body fluid alternative. Toxicol. Lett. (2001) 120(1-3):379-384.
  • MOLLOY MP, DONOHOE S, BRZEZINSKI EE et al.: Large-scale evaluation of quantitative reproducibility and proteome coverage using acid cleavable isotope coded affinity tag mass spectrometry for proteomic profiling. Proteomics (2005) 5(5):1204-1208.
  • ALONSO ME, BELLO MJ, LOMAS J et al.: Absence of mutation of the p73 gene in astrocytic neoplasms. Int. J. Oncol. (2001) 19(3):609-612.
  • JENKINSON MD, SMITH TS, JOYCE K et al.: MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology (2005) 64(12):2085-2089.
  • SCHIEBE M, OHNESEIT P, HOFFMANN W et al.: Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas. J. Cancer Res. Clin. Oncol. (2001) 127(5):325-328.
  • WESTPHAL M, HANSEL M, HAMEL W, KUNZMANN R, HOLZEL F: Karyotype analyses of 20 human glioma cell lines. Acta Neurochir. (Wien.) (1994) 126(1):17-26.
  • WILLERT JR, DANESHVAR L, SHEFFIELD VC, COGEN PH: Deletion of chromosome arm 17p DNA sequences in pediatric high-grade and juvenile pilocytic astrocytomas. Genes Chromosomes Cancer (1995) 12(3):165-172.
  • HARTMANN C, NUMANN A, MUELLER W et al.: Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma. Int. J. Cancer (2004) 108(6):839-844.
  • INO Y, SILVER JS, BLAZEJEWSKI L et al.: Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J. Neuropathol. Exp. Neurol. (1999) 58(8):881-885.
  • REY JA, BELLO MJ, JIMENEZ-LARA AM et al.: Loss of heterozygosity for distal markers on 22q in human gliomas. Int. J. Cancer (1992) 51(5):703-706.
  • NAKAMURA M, ISHIDA E, SHIMADA K et al.: Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab. Invest. (2005) 85(2):165-175.
  • MIYAKAWA A, ICHIMURA K, SCHMIDT EE, VARMEH-ZIAIE S, COLLINS VP: Multiple deleted regions on the long arm of chromosome 6 in astrocytic tumours. Br. J. Cancer (2000) 82(3):543-549.
  • BEATY RM, EDWARDS JB, BOON K et al.: PLXDC1 (TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium. J. Neurooncol. (2007) 81(3):241-248.
  • HEIMBERGER AB, MCGARY EC, SUKI D et al.: Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin. Cancer Res. (2005) 11(1):267-272.
  • SOMASUNDARAM K, REDDY SP, VINNAKOTA K et al.: Upregulation of ASCL1 and inhibition of notch signaling pathway characterize progressive astrocytoma. Oncogene (2005) 24(47):7073-7083.
  • YU S, PU P, JIANG D et al.: Relationship of bcl-2 gene expression with cell proliferation and apoptosis in human gliomas. Zhonghua Bing Li Xue Za Zhi (2000) 29(1):12-15.
  • NAKABAYASHI H, HARA M, SHIMIZU K: Prognostic significance of CDC25B expression in gliomas. J. Clin. Pathol. (2006) 59(7):725-728.
  • PERRY A, ANDERL K, BORELL TJ et al.: Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am. J. Clin. Pathol. (1999) 112(6):801-809.
  • STREGE RJ, GODT C, STARK AM, HUGO HH, MEHDORN HM: Protein expression of Fas, Fas ligand, Bcl-2 and TGFbeta2 and correlation with survival in initial and recurrent human gliomas. J. Neurooncol. (2004) 67(1-2):29-39.
  • TOHMA Y, GRATAS C, VAN MEIR EG et al.: Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J. Neuropathol. Exp. Neurol. (1998) 57(3):239-245.
  • BAGCHI A, PAPAZOGLU C, WU Y et al.: CHD5 is a tumor suppressor at human 1p36. Cell (2007) 128(3):459-475.
  • LOPEZ-GINES C, CERDA-NICOLAS M, GIL-BENSO R et al.: Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme. Clin. Neuropathol. (2005) 24(5):209-218.
  • ARSLANTAS A, ARTAN S, ONER U et al.: The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. Neurosurg. Rev. (2004) 27(1):58-64.
  • FUJISAWA H, KURRER M, REIS RM et al.: Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am. J. Pathol. (1999) 155(2):387-394.
  • MAIER D, COMPARONE D, TAYLOR E et al.: New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene (1997) 15(8):997-1000.
  • KIMMELMAN AC, ROSS DA, LIANG BC: Loss of heterozygosity of chromosome 10p in human gliomas. Genomics (1996) 34(2):250-254.
  • SCHLEGEL J, STUMM G, BRANDLE K et al.: Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J. Neurooncol. (1994) 22(3):201-207.
  • HARADA K, KURISU K, TAHARA H et al.: Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. J. Neurosurg. (2000) 93(4):618-625.
  • SAMARAS V, PIPERI C, KORKOLOPOULOU P et al.: Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol. Cell. Biochem. (2007) 304(1-2):343-351.
  • KARGIOTIS O, RAO JS, KYRITSIS AP: Mechanisms of angiogenesis in gliomas. J. Neurooncol. (2006) 78(3):281-293.
  • DESBAILLETS I, DISERENS AC, TRIBOLET N, HAMOU MF, VAN MEIR EG: Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J. Exp. Med. (1997) 186(8):1201-1212.
  • SCHIEBE M, OHNESEIT P, HOFFMANN W et al.: Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J. Neurooncol. (2000) 49(3):197-203.
  • MA Y, YUAN RQ, FAN S et al.: Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum. Anticancer Drugs (2006) 17(7):733-751.
  • LAL B, XIA S, ABOUNADER R, LATERRA J: Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin. Cancer Res. (2005) 11(12):4479-4486.
  • REIS RM, KONU-LEBLEBLICIOGLU D, LOPES JM, KLEIHUES P, OHGAKI H: Genetic profile of gliosarcomas. Am. J. Pathol. (2000) 156(2):425-432.
  • WALKER DG, DUAN W, KAYE AH, LAVIN MF: Homozygous deletions of the MTS1 gene are rare in non-astrocytic brain tumors. Biochem. Biophys. Res. Commun. (1995) 211(2):404-409.
  • KRAUS JA, WENGHOEFER M, GLESMANN N et al.: TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J. Neurooncol. (2001) 52(3):263-272.
  • WHARTON SB, MCNELIS U, BELL HS, WHITTLE IR: Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model. Neuropathol. Appl. Neurobiol. (2000) 26(6):528-535.
  • KATAYAM M, YOSHIDA K, ISHIMORI H et al.: Patched and smoothened mRNA expression in human astrocytic tumors inversely correlates with histological malignancy. J. Neurooncol. (2002) 59(2):107-115.
  • ROBINSON S, COHEN M, PRAYSON R et al.: Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas. Neurosurgery (2001) 48(4):864-873; discussion 873-864.
  • GUHA A: Platelet-derived growth factor: a general review with emphasis on astrocytomas. Pediatr. Neurosurg. (1991) 17(1):14-20.
  • SANO T, LIN H, CHEN X et al.: Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. (1999) 59(8):1820-1824.
  • SOMERVILLE RP, SHOSHAN Y, ENG C et al.: Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression. Oncogene (1998) 17(13):1755-1757.
  • WANG SI, PUC J, LI J et al.: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. (1997) 57(19):4183-4186.
  • STONE AR, BOBO W, BRAT DJ et al.: Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am. J. Pathol. (2004) 165(4):1151-1161.
  • MIZOGUCHI M, BETENSKY RA, BATCHELOR TT et al.: Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J. Neuropathol. Exp. Neurol. (2006) 65(12):1181-1188.
  • KHALIL AA, JAMES P: Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. (2007) 98(2):201-213.
  • ASSIMAKOPOULOU M, VARAKIS J: AP-1 and heat shock protein 27 expression in human astrocytomas. J. Cancer Res. Clin. Oncol. (2001) 127(12):727-732.
  • GOTTFRIED Y, VOLDAVSKY E, YODKO L et al.: Expression of the pro-apoptotic protein ARTS in astrocytic tumors: correlation with malignancy grade and survival rate. Cancer (2004) 101(11):2614-2621.
  • ARAKI K, NOZAKI K, UEBA T, TATSUKA M, HASHIMOTO N: High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas. J. Neurooncol. (2004) 67(1-2):53-64.
  • BATISTATOU A, KYZAS PA, GOUSSIA A et al.: Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours. J. Neurooncol. (2006) 77(1):17-23.
  • FLANNERY T, MCQUAID S, MCGOOHAN C et al.: Cathepsin S expression: An independent prognostic factor in glioblastoma tumours – a pilot study. Int. J. Cancer (2006) 119(4):854-860.
  • SHONO T, TOFILON PJ, BRUNER JM, OWOLABI O, LANG FF: Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. (2001) 61(11):4375-4381.
  • REN Y, MUNYER P, KEPES JJ et al.: Comparison of cyclin A and MIB-1 expression in astrocytic tumors using image-based cell analysis system. Appl. Immunohistochem. Mol. Morphol. (2001) 9(1):14-18.
  • ALLAN K, JORDAN RC, ANG LC, TAYLOR M, YOUNG B: Overexpression of cyclin A and cyclin B1 proteins in astrocytomas. Arch. Pathol. Lab. Med. (2000) 124(2):216-220.
  • DIETZMANN K, VON BOSSANYI P: Coexpression of epidermal growth factor receptor protein and c-erbB-2 oncoprotein in human astrocytic tumors. An immunohistochemical study. Zentralbl. Pathol. (1994) 140(4-5):335-341.
  • MURPHY KG, HATTON JD, U HS: Role of glial fibrillary acidic protein expression in the biology of human glioblastoma U-373MG cells. J. Neurosurg. (1998) 89(6):997-1006.
  • SHASHIDHAR S, LORENTE G, NAGAVARAPU U et al.: GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene (2005) 24(10):1673-1682.
  • MAES L, KALALA JP, CORNELISSEN M, DE RIDDER L: Progression of astrocytomas and meningiomas: an evaluation in vitro. Cell Prolif. (2007) 40(1):14-23.
  • BALENCI L, CLARKE ID, DIRKS PB et al.: IQGAP1 protein specifies amplifying cancer cells in glioblastoma multiforme. Cancer Res. (2006) 66(18):9074-9082.
  • RALTE AM, SHARMA MC, KARAK AK, MEHTA VS, SARKAR C: Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors. Pathol. Oncol. Res. (2001) 7(4):267-278.
  • PARK DM, LI J, OKAMOTO H et al.: N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation. Cell Cycle (2007) 6(4):467-470.
  • MISHIMA K, KATO Y, KANEKO MK et al.: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. (Berl.) (2006) 111(5):483-488.
  • GOPLEN D, WANG J, ENGER PO et al.: Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. (2006) 66(20):9895-9902.
  • HILTON DA, PENNEY M, EVANS B, SANDERS H, LOVE S: Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival. Am. J. Surg. Pathol. (2002) 26(4):472-478.
  • YAN B, CHOUR HH, PEH BK, LIM C, SALTO-TELLEZ M: RhoA protein expression correlates positively with degree of malignancy in astrocytomas. Neurosci. Lett. (2006) 407(2):124-126.
  • FORGET MA, DESROSIERS RR, DEL M et al.: The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. Clin. Exp. Metast. (2002) 19(1):9-15.
  • HAU P, KUNZ-SCHUGHART LA, RUMMELE P et al.: Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas. J. Neurooncol. (2006) 77(1):1-7.
  • KIM CH, BAK KH, KIM YS et al.: Expression of tenascin-C in astrocytic tumors: its relevance to proliferation and angiogenesis. Surg. Neurol. (2000) 54(3):235-240.
  • TANIOKA K, TAKESHIMA H, HIRANO H et al.: Biological role of thymidine phosphorylase in human astrocytic tumors. Oncol. Rep. (2001) 8(3):491-496.
  • NUTT CL, BETENSKY RA, BROWER MA et al.: YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin. Cancer Res. (2005) 11(6):2258-2264.
  • PELLOSKI CE, MAHAJAN A, MAOR M et al.: YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res. (2005) 11(9):3326-3334.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.